NOV 17, Mokobio Life Science was approved to list on the new OTC market and public transfer.

The note shows, Mokobio’s revenues from January to April in 2015 is ￥3.234 million, and net profit is ￥-4.36 million. The 2014 and 2013 annual revenues of the company are ￥17.75 million and ￥12.96 million, the net profit is ￥3.05 million and ￥21.1 thousand.

Data shows, Everbright Securities is Mokobio’s host broker. Sunland Law Firm is legal adviser. Baker Tilly for financial audit.

Mokobio Life Science was established in Dec 24, 2012. Main business is production, R&D and sales  in-vitro diagnostic reagents.